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Chasing Numbers
The Reinvention of Clinical Science*
William Wijns, MD, PHD, Stylianos A. Pyxaras, MD
Aalst, Belgium
Petraco et al. (1) are challenging the clinical usefulness of
applying the 0.80 cutoff values for fractional flow reserve
(FFR) when deciding about revascularization, especially
with moderate stenosis. They are discussing the potential
impact of measurement variability and misclassification
rates from uncertain FFR values, falling within the diag-
nostic gray zone, between 0.75 and 0.80. From their
statistical analysis of measurement variability within the
range of 0.70 to 0.90 FFR values, the authors claim that
uncertain findings can be found in as many as 20% of cases.
The level of uncertainty is maximal at FFR values between
0.77 and 0.83. They conclude that guidelines (2) inappro-
riately recommended the use of the 0.80 value as a
hreshold for (in)appropriate intervention.
See page 222
At first glance, the present analysis seems to provide
“scientific” support for the contention of opponents to
ischemia-guided revascularization: when measuring an in-
termediate stenosis, what you get is an intermediate FFR!
Playing with numbers. Everybody will agree that no mea-
suring technique is perfect, that both biological and mea-
surement variability should be known and accounted for
when applying the technique for clinical decision making.
Pressure-derived FFR, defined as the ratio of maximal
blood flow in a stenotic artery to normal maximal flow,
efficiently identifies the likelihood for epicardial vessel
conductance to be sufficiently reduced to cause downstream
myocardial ischemia during increased demand. As a corol-
lary, mechanical treatment by percutaneous coronary inter-
vention or coronary artery bypass grafting becomes increas-
ingly likely to augment maximal flow when applied to
stenoses with more severely reduced FFR, hence to elimi-
nate symptoms and to improve prognosis. Indeed, FFR-
guided revascularization treatment strategy has been dem-
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isclose.onstrated to improve clinical outcomes in various lesion and
patient subsets, both in randomized trials and numerous
registries, while leading to a significant change in strategy—to
treat or not to treat—in as many as one-third of cases
compared with angiographic guidance alone (3). These posi-
tive outcome data have been obtained with the 0.80 cutoff
value for FFR. If the statements by Petraco et al. (1) were
correct, implications are that the outcome data observed so far
are confounded by incorrect classifications resulting from
diagnostic uncertainty. So FFR works well but could work
even better after elimination of uncertain results. Is this real or
merely playing with numbers?
The reader should realize that the present analysis by
Petraco et al. (1) stems from a somewhat unusual “procédé.”
Their demonstration is based on the analysis of a digitized
figure published in an American Heart Association scien-
tific statement document (4), presenting reproducibility data
from the DEFER study, a study performed in the late 1990s
and published in 2001 (5). Taking the mean between 2
measurements as the real one—assuming accurate numbers
could be derived—is a misunderstanding of the physiolog-
ical principles underlying FFR, in particular its strong
dependency on achieving the highest possible level of
hyperemia. When acquiring a set of repeated and technically
adequate FFR measurements, only the lowest one should be
seen as the “real” one—not the mean value. Anyhow, the
measurement variability is low for FFR, as confirmed in a
recently published study (see Fig. 6 in Berry et al. [6]). The
FFR measurement is robust with different hyperemic agents,
injected either intravenously or directly in the coronary artery
(7). Measurement stability was verified over a wide physiolog-
cal range of heart rate and blood pressure (8).
Secondly, the equation that yields a maximal 50% inaccuracy
t the cutoff level of 0.80 erroneously assumes a normal
istribution pattern of FFR. De Bruyne et al. (9) have shown
ndeed that normal FFR values equal or approach 1.00 and
hat the probability of reduced vessel conductance increases as
FR decreases below 0.90. Therefore, the inaccuracy claim is
actitious and could be blamed on any arbitrarily selected
hreshold value. It so happens that the 0.80 threshold value was
elected for sound (patho)physiological reasons.
What about the 0.75 to 0.80 FFR gray zone? There is no gray
zone. The initial 0.75 threshold was proposed as a stringent
criterion to identify stenoses demonstrated to consistently
cause stress-induced ischemia on more than 1 noninvasive
test, normalizing in all tests after revascularization. In
clinical practice, however, ischemia was seen with FFR
values up to 0.80, and deferral of revascularization for
stenoses measured between 0.75 and 0.80 was not appro-
priate (10). Since then, all studies, both randomized and
observational, have confirmed the validity of using the 0.80
threshold as the value below which downstream ischemia
becomes highly probable and deserves treatment.
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227Barking under the wrong tree. Do all the aforementioned
mean that FFR is perfect? Of course not; yet Petraco et al.
(1) are barking under the wrong tree. Four major areas of
real uncertainty remain with FFR for clinical decision
making—assuming FFR measurements are technically cor-
rect—with avoidance and clear understanding of a number
of pitfalls.
Firstly and above all, the accuracy of FFR depends
exquisitely on the ability to induce maximal hyperemia.
There are many challenges involved, both theoretical and
practical, that cannot be discussed within the context of this
editorial comment. Yet, this is the fundamental cornerstone
of the concept, and its importance cannot be overempha-
sized. Secondly, FFR is overestimated in the presence of
high left ventricular diastolic pressures (for practical reasons,
the measurement of right atrial pressure [as a surrogate for
left ventricular diastolic pressure] has been eliminated from
the clinically used formula). Measuring FFR in nonculprit
vessels after primary percutaneous coronary intervention for
acute myocardial infarction is probably the most challenging
situation from this perspective. Ntalianis et al. (11) have
indeed shown decreasing FFR with repeated measurement
at 1 month, in the subset of patients with 20 mm Hg
end-diastolic pressure during the acute event. Thirdly,
interpretation of FFR values in vessels with diffuse disease
and/or serial focal lesions is difficult from an instrumental—
where to stent?—viewpoint. Abnormal values remain per-
tinent to the downstream myocardium, yet the relative
significance of individual lesions versus each other or versus
diffuse narrowing is difficult to discriminate, even with
motorized pressure sensor pullback during stable hyperemia.
Lastly, but not least, not enough is known about the impact
of medical therapy, stent implantation, or bypass grafting on
post-treatment FFR. Robust contemporary data on the
impact of a variable extent of restoration of epicardial
conductance on symptoms, functional consequences, and
outcomes are lacking. Most likely, one cannot assume that
focal stent implantation will “normalize” FFR in all cases.
However, the FFR principle can be used for this purpose,
because it might allow the evaluation of the quality of
reperfusion and the synergy between pharmacological and
mechanical therapy.
All the aforementioned are significant unknowns to be
considered, with important potential impact on treatment
strategies and patient outcomes whereby proper use of FFR
requires integrated patient care. The FFR should not be
used as a gatekeeper and is no excuse for go/no go–
threshold-driven Pavlovian behavior, replacing angiography
by pressure, as a trigger. We do agree in part with the final
statement by Petraco et al. (1): “. . .it would be rational for
clinicians to make revascularization decisions based on
broadened clinical judgment. . .” and “. . .all available infor- rmation (including other perfusion imaging modalities, con-
sidering anatomical features and risk-benefit profile) to
deliver safe and suitable care for individual patients.” There-
fore, we offer the following quote, which in our opinion,
remains valid over the entire range of FFR values.
“A good decision is based on knowledge and not on numbers”
—Plato, 427–347 BC, Greek philosopher
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